Importance of lean body mass in the oncologic patient

Susan Tsai

Research output: Contribution to journalArticle

Abstract

Loss of lean body develops from an imbalance in protein synthesis and catabolism and is associated with a variety of different disease and nondisease states, including severe malnutrition, cachexia, and physiologic age-related loss (sarcopenia). Loss of lean body mass is prevalent among a significant proportion of the elderly population and has been associated with increased adverse clinical outcomes. Recognition of individuals at risk for low lean body mass may be difficult due to unequal distribution of losses across muscle and adipose compartments, and individuals who are both obese and sarcopenic demonstrate the highest risk for adverse events. Cross-sectional imaging modalities provide an accessible and easily interpretable means of quantifying lean muscle content and arc routine diagnostic tests for cancer patients. As a result, a growing body of literature has developed characterizing the importance of low lean body mass as a poor prognostic factor among cancer patients, regardless of age. Cancer patients, especially those with sarcopenic obesity, are at increased risk for treatment-related toxicities from chemotherapy and increased overall mortality. Further investigations into the pathogenesis of muscle wasting among cancer patients are critical, as therapeutic oncologic interventions may inadvertently accelerate muscle catabolism. This review provides an overview of the definitions of low lean body mass, etiologic causes, clinical significance among cancer patients, and potential therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)593-598
Number of pages6
JournalNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
Volume27
Issue number5
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Muscles
Neoplasms
Sarcopenia
Cachexia
Routine Diagnostic Tests
Malnutrition
Therapeutics
Obesity
Drug Therapy
Mortality
Population
Proteins

Keywords

  • Body composition
  • Cachexia
  • Medical oncology
  • Obesity
  • Sarcopenia

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

@article{ddcd0ede2a9e4c4ab3a95173547b57a5,
title = "Importance of lean body mass in the oncologic patient",
abstract = "Loss of lean body develops from an imbalance in protein synthesis and catabolism and is associated with a variety of different disease and nondisease states, including severe malnutrition, cachexia, and physiologic age-related loss (sarcopenia). Loss of lean body mass is prevalent among a significant proportion of the elderly population and has been associated with increased adverse clinical outcomes. Recognition of individuals at risk for low lean body mass may be difficult due to unequal distribution of losses across muscle and adipose compartments, and individuals who are both obese and sarcopenic demonstrate the highest risk for adverse events. Cross-sectional imaging modalities provide an accessible and easily interpretable means of quantifying lean muscle content and arc routine diagnostic tests for cancer patients. As a result, a growing body of literature has developed characterizing the importance of low lean body mass as a poor prognostic factor among cancer patients, regardless of age. Cancer patients, especially those with sarcopenic obesity, are at increased risk for treatment-related toxicities from chemotherapy and increased overall mortality. Further investigations into the pathogenesis of muscle wasting among cancer patients are critical, as therapeutic oncologic interventions may inadvertently accelerate muscle catabolism. This review provides an overview of the definitions of low lean body mass, etiologic causes, clinical significance among cancer patients, and potential therapeutic interventions.",
keywords = "Body composition, Cachexia, Medical oncology, Obesity, Sarcopenia",
author = "Susan Tsai",
year = "2012",
month = "10",
doi = "10.1177/0884533612457949",
language = "English (US)",
volume = "27",
pages = "593--598",
journal = "Nutrition in Clinical Practice",
issn = "0884-5336",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Importance of lean body mass in the oncologic patient

AU - Tsai, Susan

PY - 2012/10

Y1 - 2012/10

N2 - Loss of lean body develops from an imbalance in protein synthesis and catabolism and is associated with a variety of different disease and nondisease states, including severe malnutrition, cachexia, and physiologic age-related loss (sarcopenia). Loss of lean body mass is prevalent among a significant proportion of the elderly population and has been associated with increased adverse clinical outcomes. Recognition of individuals at risk for low lean body mass may be difficult due to unequal distribution of losses across muscle and adipose compartments, and individuals who are both obese and sarcopenic demonstrate the highest risk for adverse events. Cross-sectional imaging modalities provide an accessible and easily interpretable means of quantifying lean muscle content and arc routine diagnostic tests for cancer patients. As a result, a growing body of literature has developed characterizing the importance of low lean body mass as a poor prognostic factor among cancer patients, regardless of age. Cancer patients, especially those with sarcopenic obesity, are at increased risk for treatment-related toxicities from chemotherapy and increased overall mortality. Further investigations into the pathogenesis of muscle wasting among cancer patients are critical, as therapeutic oncologic interventions may inadvertently accelerate muscle catabolism. This review provides an overview of the definitions of low lean body mass, etiologic causes, clinical significance among cancer patients, and potential therapeutic interventions.

AB - Loss of lean body develops from an imbalance in protein synthesis and catabolism and is associated with a variety of different disease and nondisease states, including severe malnutrition, cachexia, and physiologic age-related loss (sarcopenia). Loss of lean body mass is prevalent among a significant proportion of the elderly population and has been associated with increased adverse clinical outcomes. Recognition of individuals at risk for low lean body mass may be difficult due to unequal distribution of losses across muscle and adipose compartments, and individuals who are both obese and sarcopenic demonstrate the highest risk for adverse events. Cross-sectional imaging modalities provide an accessible and easily interpretable means of quantifying lean muscle content and arc routine diagnostic tests for cancer patients. As a result, a growing body of literature has developed characterizing the importance of low lean body mass as a poor prognostic factor among cancer patients, regardless of age. Cancer patients, especially those with sarcopenic obesity, are at increased risk for treatment-related toxicities from chemotherapy and increased overall mortality. Further investigations into the pathogenesis of muscle wasting among cancer patients are critical, as therapeutic oncologic interventions may inadvertently accelerate muscle catabolism. This review provides an overview of the definitions of low lean body mass, etiologic causes, clinical significance among cancer patients, and potential therapeutic interventions.

KW - Body composition

KW - Cachexia

KW - Medical oncology

KW - Obesity

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=84872685979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872685979&partnerID=8YFLogxK

U2 - 10.1177/0884533612457949

DO - 10.1177/0884533612457949

M3 - Article

C2 - 22898746

AN - SCOPUS:84872685979

VL - 27

SP - 593

EP - 598

JO - Nutrition in Clinical Practice

JF - Nutrition in Clinical Practice

SN - 0884-5336

IS - 5

ER -